Aquatic Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Aquatic Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-50,269	Closed	-$922K	–	1224
2024 Q4	$922K	Buy	+50,269	New	+$811K	0.03%	573
2024 Q2	–	Sell	-101,200	Closed	-$1.87M	–	1170
2024 Q1	$1.87M	Buy	101,200 +55,300	+120%	+$1.37M	0.06%	262
2023 Q4	$1.44M	Buy	45,900 +23,100	+101%	+$552K	0.04%	409
2023 Q3	$475K	Buy	+22,800	New	+$619K	0.02%	489
2023 Q2	–	Sell	-71,600	Closed	-$1.35M	–	1281
2023 Q1	$1.35M	Buy	+71,600	New	+$1.36M	0.08%	238
2022 Q4	–	Sell	-17,800	Closed	-$291K	–	1302
2022 Q3	$291K	Buy	+17,800	New	+$288K	0.03%	533
2022 Q2	–	Sell	-1,400	Closed	-$34K	–	1142
2022 Q1	$34K	Buy	+1,400	New	+$33.9K	0.05%	363

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Aquatic Capital Management's ACAD Position: Q1 2025 in Review

Aquatic Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 50,269 shares — an estimated $922K sold.

Aquatic Capital Management first reported a position in ACAD in Q1 2022 and held it in 7 quarters. The position peaked at $1.87M in Q1 2024. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

Aquatic Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Aquatic Capital Management sold 50,269 Acadia Pharmaceuticals shares in Q1 2025, an estimated $922K.
Aquatic Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Aquatic Capital Management's Acadia Pharmaceuticals position peaked at $1.87M in Q1 2024.
320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Aquatic Capital Management's 13F filing for Q1 2025, filed 15 May 2025.